Abstract
Background: CS5931, a novel marine peptide, was extracted and purified from the sea squirt Ciona savignyi. Our previous studies showed that recombinant CS5931 can significantly inhibit tumor growth both in vitro and in vivo. However, its molecular targets have not been elucidated.
Methods: The target of the recombinant CS5931 was identified by pull-down/SDS-PAGE/MS approaches and confirmed by Western blot and surface plasmon resonance analysis. Transwell experiments were used to detect whether the recombinant CS5931 inhibited cancer migration and invasion via enolase 1. Dot blotting analysis was used to detect the effect of CS5931 on the interaction of enolase 1 and plasminogen, as well as enolase 1 and uPA/uPAR.
Results: Enolase 1 was identified as the molecular target interacting with the recombinant CS5931. Transwell experiment showed that the recombinant CS5931 was able to inhibit migration and invasion of HCT116 cells and enolase 1 overexpression reversed the effects of the recombinant CS5931 on migration and invasion of cancer cells. Dot blotting analysis revealed that the recombinant CS5931 interfered with the interaction among enolase 1 and plasminogen as well as enolase 1 and uPA/uPAR.
Conclusion: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and matastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent.
Keywords: Enolase1, migration and invasion, protein-protein interaction, recombinant CS5931.
Recent Patents on Anti-Cancer Drug Discovery
Title:CS5931, A Novel Marine Polypeptide, Inhibits Migration and Invasion of Cancer Cells Via Interacting with Enolase 1
Volume: 13 Issue: 3
Author(s): Shuonan Su, Huanli Xu, Xiaoliang Chen, Gan Qiao, Ammad A. Farooqi, Ye Tian, Ru Yuan, Xiaohui Liu, Cong Li, Xiao Li, Ning Wu and Xiukun Lin*
Affiliation:
- Department of Pharmacology, Capital Medical University, Beijing 100069,China
Keywords: Enolase1, migration and invasion, protein-protein interaction, recombinant CS5931.
Abstract: Background: CS5931, a novel marine peptide, was extracted and purified from the sea squirt Ciona savignyi. Our previous studies showed that recombinant CS5931 can significantly inhibit tumor growth both in vitro and in vivo. However, its molecular targets have not been elucidated.
Methods: The target of the recombinant CS5931 was identified by pull-down/SDS-PAGE/MS approaches and confirmed by Western blot and surface plasmon resonance analysis. Transwell experiments were used to detect whether the recombinant CS5931 inhibited cancer migration and invasion via enolase 1. Dot blotting analysis was used to detect the effect of CS5931 on the interaction of enolase 1 and plasminogen, as well as enolase 1 and uPA/uPAR.
Results: Enolase 1 was identified as the molecular target interacting with the recombinant CS5931. Transwell experiment showed that the recombinant CS5931 was able to inhibit migration and invasion of HCT116 cells and enolase 1 overexpression reversed the effects of the recombinant CS5931 on migration and invasion of cancer cells. Dot blotting analysis revealed that the recombinant CS5931 interfered with the interaction among enolase 1 and plasminogen as well as enolase 1 and uPA/uPAR.
Conclusion: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and matastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent.
Export Options
About this article
Cite this article as:
Su Shuonan , Xu Huanli , Chen Xiaoliang , Qiao Gan , Farooqi A. Ammad , Tian Ye , Yuan Ru , Liu Xiaohui , Li Cong , Li Xiao, Wu Ning and Lin Xiukun *, CS5931, A Novel Marine Polypeptide, Inhibits Migration and Invasion of Cancer Cells Via Interacting with Enolase 1, Recent Patents on Anti-Cancer Drug Discovery 2018; 13 (3) . https://dx.doi.org/10.2174/1574892813666180628170240
DOI https://dx.doi.org/10.2174/1574892813666180628170240 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Calixarene: A Versatile Material for Drug Design and Applications
Current Pharmaceutical Design FDG PET/CT in the Staging of Lung Cancer
Current Radiopharmaceuticals Editorial [Hot Topic: Protein Kinase Inhibitors: Current Strategies and Future Prospects (Executive Guest Editor: Julio Caballero)]
Current Pharmaceutical Design Novel Findings on Trypanosomatid Chemotherapy Using DNA Topoisomerase Inhibitors
Mini-Reviews in Medicinal Chemistry In Silico Analysis and Molecular Docking Studies of Novel 6,7-dihydropyrano [2,3-d] pyrimidin-5-one Derivatives as Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR) Inhibitors
Current Cancer Therapy Reviews Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Current Pharmaceutical Design Female Infertility and Assisted Reproduction: Impact of Oxidative Stress-- An Update
Current Women`s Health Reviews Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Demethylating Agents as Epigenetic Anticancer Therapeutics
Current Cancer Therapy Reviews Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Alpha-Helical Cationic Anticancer Peptides: A Promising Candidate for Novel Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status
Current Respiratory Medicine Reviews Design, Synthesis, and Docking Studies of 4H-Chromene and Chromene Based Azo Chromophores: A Novel Series of Potent Antimicrobial and Anticancer Agents
Current Organic Synthesis Endothelial Cells in Inflammation and Angiogenesis
Current Drug Targets - Inflammation & Allergy Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy
Current Cancer Drug Targets